| Domain | Curated finding | Ontology/identifier suggestions | Evidence strength/gap |
|---|---|---|---|
| Definition and nomenclature | Rumination disorder/syndrome is a disorder of gut-brain interaction / feeding-related disorder characterized by recurrent, effortless regurgitation of recently ingested food, typically soon after meals, due to a learned behavioral pattern rather than primary acid reflux or structural disease; literature uses both **rumination disorder** and **rumination syndrome**. It can be mistaken for PPI-refractory GERD and should be distinguished from vomiting, GERD, and supragastric belching (pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: MONDO term for rumination disorder/syndrome; MeSH/ICD-11/DSM-5 terminology alignment; related ontology concepts: disorder of gut-brain interaction, feeding and eating disorder | Moderate-strong clinical/guideline evidence; identifier harmonization remains a curation task |
| Key phenotype | Core phenotype is **postprandial repetitive regurgitation** of recently ingested food, usually effortless and not preceded by retching; episodes are often triggered by habitual abdominal wall contraction and may lessen when contents become acidic (pqac-00000005, pqac-00000006, pqac-00000007). | Suggested mappings requiring validation: HPO terms for regurgitation, postprandial symptom exacerbation, nausea/fullness/epigastric discomfort where present | Strong for core symptom; phenotype frequency/severity distributions remain incompletely standardized across cohorts |
| Mechanism / pathophysiology | Current understanding supports a **behavioral-somatic mechanism**: food ingestion is followed by unintentional abdomino-thoracic/abdominal wall contraction with relaxation of esophageal sphincter mechanisms, producing retrograde flow of gastric contents. Breathing-based therapies likely work by interrupting this motor pattern; vagal modulation is under investigation (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000005, pqac-00000006). | Suggested mappings requiring validation: GO terms related to motor behavior, muscle contraction, autonomic regulation; CL terms for skeletal muscle cell, enteric neuron, vagal-related autonomic neuron | Moderate mechanistic evidence from physiology and interventional studies; molecular pathway detail is limited |
| Anatomy | Primary affected structures are the **stomach**, **esophagus**, **lower esophageal sphincter region**, **diaphragm**, and **abdominal wall musculature**; the syndrome reflects abnormal coordination across upper GI and respiratory/abdominal motor systems rather than a focal tissue lesion (pqac-00000001, pqac-00000002, pqac-00000003). | Suggested mappings requiring validation: UBERON terms for stomach, esophagus, diaphragm, abdominal wall musculature, lower esophageal sphincter | Moderate evidence from manometric/physiologic studies; no specific histopathologic lesion established |
| Epidemiology | Population burden is recognized globally, but precise prevalence varies by diagnostic framework and ascertainment; recent reviews/meta-analytic work exist but exact pooled estimates were not available in the retrieved evidence set here. Rumination is likely under-recognized and misdiagnosed as reflux-related disease (pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: epidemiology annotation for global distribution, pediatric and adult onset | Evidence gap in this artifact: recent prevalence estimates should be added from primary epidemiology/meta-analysis sources before KB finalization |
| Diagnosis | Diagnosis is primarily **clinical**, supported when needed by **high-resolution impedance manometry** and/or **ambulatory pH-impedance monitoring** to distinguish rumination from GERD and belching disorders. Diagnostic workup should exclude relevant organic disease but avoid excessive low-yield testing (pqac-00000000, pqac-00000001, pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: diagnostic procedure terms for clinical assessment, high-resolution impedance manometry, ambulatory pH-impedance monitoring | Strong expert-consensus and trial-supportive evidence |
| First-line treatment | **Behavioral therapy** is first-line, especially **diaphragmatic breathing** and structured **cognitive-behavioral therapy for rumination disorder/syndrome (CBT-RD/CBT-RS)** targeting habit reversal and competing responses to abdominal wall contraction (pqac-00000000, pqac-00000005, pqac-00000006, pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: MAXO terms for behavioral therapy, diaphragmatic breathing training, cognitive behavioral therapy, habit reversal | Strongest current treatment evidence; supported by physiologic rationale and interventional studies |
| Adjunct treatment | **Biofeedback** (including EMG-guided biofeedback) has randomized trial support as a nonpharmacologic adjunct. **Baclofen** has been studied in placebo-controlled crossover trials and pediatric investigation as an adjunct when behavioral therapy is insufficient or unavailable (pqac-00000001, pqac-00000002, pqac-00000003). | Suggested mappings requiring validation: MAXO terms for biofeedback, electromyographic biofeedback, baclofen therapy | Moderate evidence; smaller studies/trials, and long-term comparative effectiveness remains limited |
| Genetics / omics | **No monogenic causal gene, pathogenic variant, chromosomal abnormality, validated susceptibility locus, molecular biomarker, transcriptomic signature, proteomic signature, metabolomic signature, or epigenetic marker is established for rumination disorder/syndrome.** No validated germline or somatic genetic testing approach is currently indicated (pqac-00000005, pqac-00000006, pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: “no established gene-disease association”; “no validated biomarker” annotations | Major evidence gap / likely non-applicable at present |
| Prognosis | Prognosis is generally tied to **recognition and response to behavioral treatment**; chronic symptoms, diagnostic delay, nutritional compromise, psychosocial burden, and reduced quality of life can occur, but disease-specific mortality is not established in available evidence here. Misdiagnosis may prolong morbidity (pqac-00000005, pqac-00000006, pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: annotations for chronic/relapsing course, quality-of-life impact, nutritional complications | Moderate evidence for morbidity; quantitative long-term natural history remains limited in this evidence set |
| Prevention | There is **no established primary prevention** based on genetics, infection, toxin, or environmental exposure. Practical prevention focuses on **early recognition**, avoidance of unnecessary reflux escalation/surgery, patient education, and prompt access to behavioral therapy to reduce chronicity and complications (pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: secondary prevention via early diagnosis; tertiary prevention via behavioral management and nutritional support | Moderate expert-opinion evidence; no formal public-health prevention program established |
| Environmental / infectious / toxic causes | **No infectious agent, toxin, radiation exposure, pollutant, or occupational exposure has been established as a primary cause.** The disorder is best understood as a learned behavioral/physiologic pattern within gut-brain interaction frameworks (pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: “no established infectious etiology”; “no established toxic etiology” | Evidence gap / negative finding based on current understanding |
| Animal models / other species | **No validated animal model or naturally occurring nonhuman disease model is established for rumination disorder/syndrome**, consistent with the disorder’s human behavioral-physiologic phenotype and reliance on symptom report/manometry-based characterization (pqac-00000005, pqac-00000006, pqac-00000007, pqac-00000008). | Suggested mappings requiring validation: “no validated model organism” annotation | Major evidence gap / likely non-applicable at present |


*Table: This table summarizes core knowledge-base findings for rumination disorder/syndrome across definition, mechanism, diagnosis, treatment, and evidence gaps. It is designed for rapid curation and explicitly flags domains where no validated genetic, biomarker, infectious, toxic, or animal-model evidence is established.*